668 related articles for article (PubMed ID: 23933113)
1. A high content screening assay to predict human drug-induced liver injury during drug discovery.
Persson M; Løye AF; Mow T; Hornberg JJ
J Pharmacol Toxicol Methods; 2013; 68(3):302-13. PubMed ID: 23933113
[TBL] [Abstract][Full Text] [Related]
2. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.
Chen M; Tung CW; Shi Q; Guo L; Shi L; Fang H; Borlak J; Tong W
Arch Toxicol; 2014 Jul; 88(7):1439-49. PubMed ID: 24958025
[TBL] [Abstract][Full Text] [Related]
3. Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays.
Shah F; Leung L; Barton HA; Will Y; Rodrigues AD; Greene N; Aleo MD
Toxicol Sci; 2015 Oct; 147(2):500-14. PubMed ID: 26206150
[TBL] [Abstract][Full Text] [Related]
4. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.
Proctor WR; Foster AJ; Vogt J; Summers C; Middleton B; Pilling MA; Shienson D; Kijanska M; Ströbel S; Kelm JM; Morgan P; Messner S; Williams D
Arch Toxicol; 2017 Aug; 91(8):2849-2863. PubMed ID: 28612260
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.
Tomida T; Okamura H; Satsukawa M; Yokoi T; Konno Y
Toxicol Lett; 2015 Jul; 236(1):16-24. PubMed ID: 25934330
[TBL] [Abstract][Full Text] [Related]
6. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.
Weaver RJ; Betts C; Blomme EAG; Gerets HHJ; Gjervig Jensen K; Hewitt PG; Juhila S; Labbe G; Liguori MJ; Mesens N; Ogese MO; Persson M; Snoeys J; Stevens JL; Walker T; Park BK
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):767-782. PubMed ID: 28604124
[TBL] [Abstract][Full Text] [Related]
7. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury.
Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315
[TBL] [Abstract][Full Text] [Related]
8. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.
Tolosa L; Pinto S; Donato MT; Lahoz A; Castell JV; O'Connor JE; Gómez-Lechón MJ
Toxicol Sci; 2012 May; 127(1):187-98. PubMed ID: 22331495
[TBL] [Abstract][Full Text] [Related]
9. High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins.
Tolosa L; Carmona A; Castell JV; Gómez-Lechón MJ; Donato MT
Arch Toxicol; 2015 Oct; 89(10):1847-60. PubMed ID: 25160661
[TBL] [Abstract][Full Text] [Related]
10. A human liver organoid screening platform for DILI risk prediction.
Zhang CJ; Meyer SR; O'Meara MJ; Huang S; Capeling MM; Ferrer-Torres D; Childs CJ; Spence JR; Fontana RJ; Sexton JZ
J Hepatol; 2023 May; 78(5):998-1006. PubMed ID: 36738840
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations.
Albrecht W; Kappenberg F; Brecklinghaus T; Stoeber R; Marchan R; Zhang M; Ebbert K; Kirschner H; Grinberg M; Leist M; Moritz W; Cadenas C; Ghallab A; Reinders J; Vartak N; van Thriel C; Golka K; Tolosa L; Castell JV; Damm G; Seehofer D; Lampen A; Braeuning A; Buhrke T; Behr AC; Oberemm A; Gu X; Kittana N; van de Water B; Kreiling R; Fayyaz S; van Aerts L; Smedsrød B; Ellinger-Ziegelbauer H; Steger-Hartmann T; Gundert-Remy U; Zeigerer A; Ullrich A; Runge D; Lee SML; Schiergens TS; Kuepfer L; Aguayo-Orozco A; Sachinidis A; Edlund K; Gardner I; Rahnenführer J; Hengstler JG
Arch Toxicol; 2019 Jun; 93(6):1609-1637. PubMed ID: 31250071
[TBL] [Abstract][Full Text] [Related]
12. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening.
O'Brien PJ; Irwin W; Diaz D; Howard-Cofield E; Krejsa CM; Slaughter MR; Gao B; Kaludercic N; Angeline A; Bernardi P; Brain P; Hougham C
Arch Toxicol; 2006 Sep; 80(9):580-604. PubMed ID: 16598496
[TBL] [Abstract][Full Text] [Related]
13. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.
Tolosa L; Jiménez N; Pérez G; Castell JV; Gómez-Lechón MJ; Donato MT
Arch Toxicol; 2018 Jan; 92(1):383-399. PubMed ID: 28762043
[TBL] [Abstract][Full Text] [Related]
14. High-content screening technology for studying drug-induced hepatotoxicity in cell models.
Tolosa L; Gómez-Lechón MJ; Donato MT
Arch Toxicol; 2015 Jul; 89(7):1007-22. PubMed ID: 25787152
[TBL] [Abstract][Full Text] [Related]
15. Predicting drug-induced liver injury in human with Naïve Bayes classifier approach.
Zhang H; Ding L; Zou Y; Hu SQ; Huang HG; Kong WB; Zhang J
J Comput Aided Mol Des; 2016 Oct; 30(10):889-898. PubMed ID: 27640149
[TBL] [Abstract][Full Text] [Related]
16. A rapid mitochondrial toxicity assay utilizing rapidly changing cell energy metabolism.
Sanuki Y; Araki T; Nakazono O; Tsurui K
J Toxicol Sci; 2017; 42(3):349-358. PubMed ID: 28496041
[TBL] [Abstract][Full Text] [Related]
17. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.
Laifenfeld D; Qiu L; Swiss R; Park J; Macoritto M; Will Y; Younis HS; Lawton M
Toxicol Sci; 2014 Jan; 137(1):234-48. PubMed ID: 24136188
[TBL] [Abstract][Full Text] [Related]
18. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes.
Garside H; Marcoe KF; Chesnut-Speelman J; Foster AJ; Muthas D; Kenna JG; Warrior U; Bowes J; Baumgartner J
Toxicol In Vitro; 2014 Mar; 28(2):171-81. PubMed ID: 24189122
[TBL] [Abstract][Full Text] [Related]
20. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
Chen M; Borlak J; Tong W
Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
